Hagedorn Research Institute
Department of Stem Cell Biology
Niels Steensens vej 6
DK-2820 Gentofte
Project leader
 |
|
Project staff
 |
|
 |
|
Institute presentation
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Hagedorn Research Institute (HRI) in Gentofte, Denmark is a fully integrated part of Novo Nordisk. Our vision is to find a cure for diabetes and its complications and to identify new opportunities for treating diabetes. Our core focus is the effort to identify new biology-based targets for potential drugs to feed Novo Nordisk’s pipeline within the key areas of diabetes pathogenesis, treatment and cure. The aim of the Stem Cell Biology department is to develop cell replacement therapy into a viable option for treating Diabetes Mellitus. The reconstitution of a functional beta cell mass can restore blood glucose homeostasis in diabetic patients and eliminates the need for insulin injections. Our main objective is to generate clinical-grade pancreatic beta cells from pluripotent stem cells by harnessing their differentiation potential and to recapitulate the complex process of beta cell formation in vitro.